Key result
Vasoplegic syndrome after cardiac surgery lacks standardized diagnostic and treatment methods, though vasopressin is likely the most effective first-line vasopressor.
Why the study?
Vasoplegic syndrome is an increasing problem affecting morbidity and mortality in patients undergoing cardiac surgery, but standardized methods for its diagnosis and treatment are lacking.
This review highlights vasopressin as a first-line vasopressor and methylene blue or hydroxocobalamin as promising alternative therapies for managing vasoplegic syndrome after cardiac surgery.
May support vasopressin preference amid diagnostic gaps; hypothesis-generating for standardization and alternatives.
Vasoplegic syndrome is a rising problem affecting morbidity and mortality in patients undergoing cardiac surgery. Vasoplegia is a vasodilatory, shocklike syndrome characterized by decreased systemic vascular resistance, normal to high cardiac index, and hypotension refractory to fluid resuscitation and vasopressors. This review describes the presentation, physiology, risk factors, treatments, and implications of vasoplegia after cardiac surgery. No standardized methods for diagnosing and treating vasoplegia are available. Vasoplegia is caused by surgical trauma, systemic inflammation, and vascular dysregulation. Patients with comorbidities and those undergoing complex surgical procedures are at increased risk for vasoplegia. The use of β-blockers is protective. Vasoplegia is potentially reversible. Vasopressin is likely the most effective first-line vasopressor, and the use of methylene blue and/or hydroxocobalamin may restore vascular tone. Alternative therapies such as methylene blue and hydroxocobalamin show promise, but additional research and education are needed.
No takes yet. Share an insight, caveat, or question.
Colleen M. Nash (2021) conducted a review in Vasoplegic syndrome after cardiac surgery. Vasoplegic syndrome after cardiac surgery lacks standardized diagnostic and treatment methods, though vasopressin is likely the most effective first-line vasopressor.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: